Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) supports teams developing adaptive drug and biologic trials to evaluate treatments faster, at lower cost, and with fewer participants.
Funder: Advanced Research Projects Agency for Health
Due Dates: November 5, 2026 (Virtual event registration) | November 6, 2026 (Proposers’ Day) | November 30, 2026 (Solution Summary) | January 22, 2027 (Proposal)
Funding Amounts: Consult the official solicitation for funding details.
Summary: SURPASS supports adaptive platform trials, real-time inference, and automated operations to evaluate drugs and biologics faster, at lower cost, and with fewer participants.
Key Information: A Solution Summary and ARPA-H feedback are required before submitting a Solution Pitch package.
Description
The Advanced Research Projects Agency for Health (ARPA-H) runs SURPASS to modernize clinical development of drugs and biologics. The program seeks perpetual, adaptive platform trials combining predictive computational models, shared trial infrastructure, common control groups, and real-time analysis. Its goal is to reduce trial time, cost, and participant burden while enabling earlier decisions about which treatments work.
SURPASS seeks cross-disciplinary teams bringing together statistics, artificial intelligence, clinical trial design and operations, regulatory science, and patient-centered design. Three coordinated technical areas address faster trials with fewer patients, a continuous inference engine for faster decisions, and an agentic operations layer to reduce time and cost. The program aims to build shared infrastructure and new standards that help effective treatments reach patients sooner.
